COVID-19 booster effectiveness remained high during Omicron surge
On Apr. 18, 2022, the Military Health System reported that active-duty service members who received a COVID-19 vaccine…
Pfizer and BioNTech data demonstrated high immune response following booster dose of COVID-19 vaccine in children 5 through 11 years of age
On Mar. 14, 2022, Pfizer and BioNTech announced positive results from a Phase 2/3 clinical trial evaluating the…
Merck announced FDA granted breakthrough therapy designation for V116, investigational 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults
On Apr. 14, 2022, Merck announced that V116, the companyï¾’s investigational 21-valent pneumococcal conjugate vaccine, had received Breakthrough…
Swissmedic granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Apr. 13, 2022, Novavax announced that Swissmedic had granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19…
CureVac and GSK entered into Pandemic preparedness contract with German government Candidate, CV2CoV
On Apr. 11, 2022, CureVac and GSK announced that they had entered into a contract with the German…
BioNTech granted pandemic preparedness contract by German Federal Ministry of Health
On Apr. 9, 2022, BioNTech announced it was granted a pandemic preparedness contract by the Federal Republic of…
USDA confirmed highly pathogenic Avian influenza in Texas
On Apr. 3, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
Novavax submitted request to expand conditional Marketing Authorization of COVID-19 vaccine in the EU to adolescents
On Mar. 31, 2022, Novavax announced submission of its request to expand the conditional marketing authorization (CMA) of…
NIH began clinical trial evaluating second COVID-19 booster shots in adults
On Mar. 31, 2022, the National Institutes of Health and Moderna announced a phase 2 clinical trial evaluating…
CureVac and GSK started clinical development of second-generation COVID-19 vaccine Candidate, CV2CoV
On Mar. 30, 2022, CureVac announced that the first participant was dosed in a Phase 1 study of…
Pfizer and BioNTech received expanded U.S. EUA for additional COVID-19 vaccine booster in individuals Aged 50 Years and older
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
Moderna finalized strategic partnership with Australian government
On Mar. 23, 2022, Moderna announced the finalization of a strategic partnership with the Australian Federal Government to…
Moderna announced COVID-19 vaccine phase 2/3 study in children 6 months to Under 6 years met Its primary endpoint
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
Moderna announced new supply agreement for 2023 with Switzerland for seven million doses of COVID-19 booster vaccine
On Mar. 21, 2022, Moderna announced announced a new supply agreement with the Swiss Federal Government for seven…
More than 80 million doses administered to southern African children targeted in mass polio vaccination drives
On Mar. 18, 2022, the World Health Organization (WHO) announced that Malawi had launched the first round of…
Health Canada authorized Moderna’s COVID-19 vaccine in children (6-11 Years)
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
Eiger’s single-dose Peginterferon Lambda for COVID-19 reduced risk of hospitalization or ER visits by 50% in vaccinated population
On Mar. 17, 2022, Eiger BioPharmaceuticals announced that Peginterferon Lambda (Lambda) significantly reduced the risk of COVID-19-related hospitalizations…
Soligenix COVID-19 vaccine, CiVax, boosted neutralizing activity against SARS-CoV-2, including Delta and Omicron
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax (heat stable COVID-19…
Moderna to supply Japan with additional 70 million doses of COVID-19 booster vaccine
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
Pfizer and BioNTech submitted for U.S. EUA of additional booster dose of COVID-19 vaccine for older adults
On Mar. 15, 2022, Pfizer and BioNTech announced the companies had submitted an application to the U.S. Food…
COVID-19 | HIV | NIH | Non-Profit Research | Vaccine
NIH launched clinical trial of three mRNA HIV vaccines
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) has launched a…
Oragenics engages KBI Biopharma to support development of intranasal COVID-19 vaccine candidate NT-CoV2-1
On Mar. 10, 2022, Oragenics announced that it had entered into an agreement with KBI Biopharma for the…
Moderna announced first participant dosed in phase 2 study of Omicron-specific bivalent booster candidate
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
IHME reported three times as many deaths worldwide due to COVID-19 than official reports suggested
On Mar. 10, 2022, the Institute for Health Metrics and Evaluation (IHME) reported that more than three times…
City of Hope COVID-19 vaccine showed effectiveness in phase 1 trial
On Mar. 10, 2022, the City of Hope announced that its COVID-19 investigational vaccine licensed to GeoVax Labs…
NIH launched trial to study allergic reactions to COVID-19 mRNA vaccine
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
Moderna announced MOU with Government of Kenya to establish first mRNA manufacturing facility on the continent of Africa
On Mar. 7, 2022, Moderna announced that with the assistance of the U.S. Government, it had entered into…
First-ever malaria vaccine recommendation published in a position paper and in the WHO guidelines for malaria
On Mar. 4, 2022, the WHO announced it had published an updated position paper on the RTS,S/AS01 (RTS,S)…
EMA’s Committee for Medicinal Products for Human Use recommended authorization of Covid-19 vaccine in children (6-11 Years) In the EU
On Feb. 24, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
Pfizer and BioNTech received positive CHMP Opinion for COVID-19 vaccine booster in adolescents 12 through 17 years of age in EU
On Feb. 24, 2022, BioNTech announced that the Committee for Medicinal Products for Human Use of the European…